Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib with or without Bevacizumab in EGFR-mutant NSCLC
NCT01532089Phase 2Completed
- Sponsor
- Academic and Community Cancer Research United
- Start
- Mar 2012
- Primary completion
- Feb 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Academic and Community Cancer Research United. Started Mar 2012; status: completed.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01532089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01532089.